An itching drug that was a key part of the merger of Menlo Therapeutics and Foamix Pharmaceuticals has failed two late-stage studies, leading to a halt on further development of the compound.
GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer.
The partnership will leverage antibody technology from Vir... Read more »
Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy’s free special report delivers the latest COVID-19 news from the frontlines as top biotech and investment players... Read more »
The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion.
Parkinson’s disease patients experience progressive breakdown of their neurons, cells essential to movement and mental function. Aspen Neuroscience, a biotech working to develop a therapy that would reprogram those patients’ own living cells in ways that would allow the cells to... Read more »
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.
Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials... Read more »
Two companies working on treatments for rare genetic lung diseases have combined efforts and raised $80 million to bring into human testing next year two investigational treatments that use types of RNA to tweak mutated proteins.
Dallas company ReCode Therapeutics and... Read more »
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs.
That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade”... Read more »
CytomX Therapeutics is teaming up with Astellas Pharma in a research and development alliance focused on developing new cancer immunotherapies based on its antibody technology.
Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US Food and Drug Administration. Most notably, it must get physician practices and individual allergists certified to administer... Read more »
Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic.
To enhance its chances of success, the Emeryville, CA-based company... Read more »
Culture Biosciences, a contract development and manufacturing organization, has added new funding to increase bioreactor capacity and create additional monitoring software.
The San Francisco startup announced the completion of a $15 million Series A financing round this week, bringing aboard fresh... Read more »
Cell therapies have helped treat some blood cancers, but toxic side effects are one limitation preventing their use in solid tumors.
Amunix has, since its 2006 launch, licensed to biopharmas technology developed by company co-founder Volker Schellenberger to extend the half-life... Read more »
The nomination period for the 2020 National Xconomy Awards is now open. The awards are open to individuals, companies, and organizations working across the life sciences in the United States, and feature leaders in the biotech industry, medicine, academia, digital health,... Read more »
Cancer immunotherapy’s use can be limited by its side effects throughout the body. Xilio Therapeutics is developing technology that selectively activates a therapy’s potent cancer-killing activity specifically at the tumor and it has raised $100.5 million to advance two programs to... Read more »
Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment.
The Cambridge, MA-based neuroscience drug developer is paying gene editing company Sangamo Therapeutics... Read more »
An investigational antiviral drug Gilead Sciences has been developing to treat infections caused by the Ebola virus will be tested in about 1,000 adults diagnosed with COVID-19, the novel coronavirus that has infected tens of thousands of people and killed more... Read more »
In what looks to be a transformative year for potential treatments of nonalcoholic steatohepatitis, the liver disease better known as NASH, another biotech has revealed that its experimental drug appears to improve the condition compared to a placebo.
NGM Biopharmaceuticals (NASDAQ:... Read more »